Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RMC-4630 |
Synonyms | |
Therapy Description |
RMC-4630 is an inhibitor of SHP2 (PTPN11) that prevents MAPK signaling and cell growth (PMID: 31727671). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RMC-4630 | RMC-4630-02|SAR442720|SAR 442720 | SHP2 Inhibitor 20 | RMC-4630 is an inhibitor of SHP2 (PTPN11) that prevents MAPK signaling and cell growth (PMID: 31727671). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03634982 | Phase I | RMC-4630 | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors | Unknown status | USA | 0 |